← All causality assessments
Expected pharmacological effect
Causality assessment · Expected pharmacological effect
Flurazepam Hydrochloride and Drug Abuse: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Flurazepam Hydrochloride ↔ Drug Abuse
n=65 co-reports · PRR 41.3 · ROR 49.2
Lenalidomide is an immunomodulatory IMiD for multiple myeloma. Co-reporting of multiple myeloma as a reaction is a coding artifact: patients on lenalidomide for myeloma have the indication recorded as the AE. 2,216 co-reports (PRR 14.5) reflect the treated population.
Coding artifact: multiple myeloma is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Flurazepam captured drug abuse as a tracked adverse event in a usable structure. Multiple myeloma is the indication; trials do not track it as an AE.